

August 2020

CENTER FOR VACCINE INNOVATION & ACCESS (CVIA)

# 10th Policy Actions for COVID-19 Economic Recovery (PACER) Dialogues

## Enhancing Readiness for Large-Scale Vaccine Distribution Amid COVID-19


This is not an ADB material. The views expressed in this document are the views of the author/s and/or their organizations and do not necessarily reflect the views or policies of Asian Development Bank, or its Board of Governors, or the governments they represent. ADB does not guarantee the accuracy and/or completeness of the material's contents, and accepts no responsibility for any direct or indirect consequence of their use or reliance, whether wholly or partially. Please feel free to contact the authors should you have queries.

# Vaccine delivery

- Huong Vu



# Vaccine Delivery Overview



**Planning:** Ministries and partners to prioritize populations, assess vaccine suitability, determine resource requirements, and develop access and introduction plan for COVID-19 vaccines.

**System:** Assess and strengthen capacity for delivery, including training, reporting, and logistics, as well as communications and monitoring and evaluation.

**Finance:** Determine the costs associated with procurement and delivery of COVID-19 vaccines.

# Vaccine Introduction Planning Activities

## Convene

- Define decision making processes and develop a stakeholder coordination plan for prioritization, finance, and delivery
- SAGE, NITAG, ICC, etc. provide technical guidance on clinical trial data, programmatic, social, and economic implications

## Evaluate

- Define priority populations for vaccination and feasible delivery strategies
- Assess system readiness, logistics and personnel capacity, resource needs

## Plan

- Develop a COVID-19 Vaccine Introduction Strategic Plan

# Potential Complexities Associated with Early COVID-19 Vaccine Introduction

## Vaccine suitability

- All vaccines licensed by recognized national regulatory authorities will meet minimum target product profiles; however, characteristics will vary, including:
  - Formulation (liquid vs. lyophilized)
  - Dosing schedules
  - Method of delivery (intramuscular vs. intradermal)
  - Packaging and cold chain requirements (2-8°C vs -70°C)
- Given the different vaccine platforms, vaccines may perform differently depending on target population; thus, products are unlikely to be interchangeable.
- Each vaccine product may pose unique delivery challenges, complicating planning, communication, training, and reporting.

## Delivery strategies

- Creation of new and innovative delivery channels will be required to reach priority target populations
- Campaign outreach is complicated with physical distancing orders in place
- Frequent, clear communication about the benefits and risks of vaccination will be essential to minimize misinformation and vaccine hesitancy
- Introduction of COVID-19 vaccine should avoid interrupting (and potentially strengthen) routine immunization services

# Vaccine Delivery Planning Timeline Considerations

4Q2020

1Q2021

2Q2021

3Q2021

EPI review/EVMA

cMYP development

National Health Plan 2021-2025 development



Coordination

Logistics readiness assessment

COVID-19 vaccine introduction strategic plan

Communication

It is important for countries to consider how to integrate COVID-19 vaccine into these plans without further disrupting existing routine immunization or health services

-  Routine immunization planning
-  COVID-19 planning

Thank you

